These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 2694627)

  • 1. [Treatment of hyperlipidemia with HMG-CoA reductase inhibitors].
    Prager R
    Wien Med Wochenschr Suppl; 1989; 105():17-20. PubMed ID: 2694627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New perspectives in the control of hypercholesterolemia with the use of HMG CoA reductase inhibitors].
    Ribeiro L; Kohn IJ
    Arq Bras Cardiol; 1990 Mar; 54(3):177-8. PubMed ID: 2288502
    [No Abstract]   [Full Text] [Related]  

  • 4. [HMG-CoA reductase inhibitor for therapy of patients with hyperlipoproteinemia ].
    Jingami H
    Nihon Rinsho; 1994 Dec; 52(12):3271-8. PubMed ID: 7853722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia].
    Prat H; Román O; Pino E
    Rev Med Chil; 1999 Mar; 127(3):286-94. PubMed ID: 10436712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HMG-CoA reductase inhibitors: a look back and a look ahead.
    Davignon J; Montigny M; Dufour R
    Can J Cardiol; 1992 Oct; 8(8):843-64. PubMed ID: 1423005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of clinical trials comparing HMG-CoA reductase inhibitors.
    Illingworth DR; Tobert JA
    Clin Ther; 1994; 16(3):366-85; discussion 365. PubMed ID: 7923304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
    Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
    Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lovastatin: a new cholesterol-lowering agent.
    McKenney JM
    Clin Pharm; 1988 Jan; 7(1):21-36. PubMed ID: 3278832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of nicotinic acid and lovastatin in combination with cholestyramine in renal transplant patients.
    Lal SM; Katyal A
    Mo Med; 2002; 99(10):580-4. PubMed ID: 12534147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors.
    Tobert JA
    Nat Rev Drug Discov; 2003 Jul; 2(7):517-26. PubMed ID: 12815379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug therapy of severe hypercholesterolemia.
    Weizel A; Richter WO
    Eur J Med Res; 1997 Jun; 2(6):265-9. PubMed ID: 9182654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity.
    Pazzucconi F; Dorigotti F; Gianfranceschi G; Campagnoli G; Sirtori M; Franceschini G; Sirtori CR
    Atherosclerosis; 1995 Oct; 117(2):189-98. PubMed ID: 8801864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
    Chang JT; Staffa JA; Parks M; Green L
    Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
    Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
    Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
    Martens LL; Guibert R
    Clin Ther; 1994; 16(6):1052-62; discussion 1036. PubMed ID: 7697684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pleiotropic effects of HMG-CoA reductase inhibitors.
    Bocan TM
    Curr Opin Investig Drugs; 2002 Sep; 3(9):1312-7. PubMed ID: 12498006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
    Branchi A; Rovellini A; Sommariva D; Gugliandolo AG; Fasoli A
    Thromb Haemost; 1993 Aug; 70(2):241-3. PubMed ID: 8236126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholesterol homeostasis in mononuclear leukocytes from patients with familial hypercholesterolemia treated with lovastatin.
    Hagemenas FC; Illingworth DR
    Arteriosclerosis; 1989; 9(3):355-61. PubMed ID: 2719596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of the HMG-CoA-reductase inhibitor lovastatin on cholesterol saturation index and nucleation time of duodenal bile.
    Nitsche R; Schlage J; Ramin V; Kirchhoff S; Fölsch UR; Creutzfeldt C; Creutzfeldt W
    Z Gastroenterol; 1991 May; 29(5):242-5. PubMed ID: 1950033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.